PMC:6986229 / 7544-7845 JSONTXT

{"project":"LitCovid-sentences","denotations":[{"id":"T63","span":{"begin":0,"end":86},"obj":"Sentence"},{"id":"T64","span":{"begin":87,"end":170},"obj":"Sentence"},{"id":"T65","span":{"begin":171,"end":301},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The annual cost of trastuzumab from originator companies can be as high as US$ 20 000. The biosimilar version of trastuzumab is generally 65% cheaper than the originator. With this WHO listing, and more products expected in the prequalification pipeline, treatment prices should decrease even further."}